1. At a Glance
Jagsonpal Pharma just dropped a Q1 mic: revenue up 23% YoY to ₹756 Mn, PAT doubled to ₹108 Mn, and cash reserves at ₹1,609 Mn. The stock’s up 4% because investors finally stopped napping. The CFO resigned right after, probably because even he couldn’t believe these margins.
2. Introduction with Hook
Imagine a startup that sells hope in blister packs but without the drama of an IPO. Jagsonpal is that auntie who’s been around since 1978, still rocking it at weddings while the young ones gasp. Two fun facts:
- Revenue grew 23% in Q1 FY26.
- PAT didn’t just grow—it doubled. Yes, pharma profits now beat your FD returns by a mile.
3. Business Model (WTF Do They Even Do?)
Jagsonpal basically makes medicines for women’s health, bones that crack, and other “please fix me” problems.
- Gynaecology & Orthopaedics = cash cows.
- Other plays: antibiotics, allergy, immunity, OTC, dermatology, pediatrics.
- They have 17 brands in Top 5 molecules—basically the overachievers of pharma.
Punchline: “They sell pills that fix people and pad wallets—like an ethical drug dealer.”
4. Financials Overview
Q1 FY26 Snapshot:
- Revenue: ₹756 Mn (YoY +23%)
- PAT: ₹108 Mn (YoY +100%)
- OPM: 19% (Margins looking healthier than your gym trainer)
- EPS: ₹1.62
Commentary: Margins tighter than a Mumbai parking spot, but somehow they keep growing profits like weeds in monsoon.
5. Valuation
Jagsonpal trades at a P/E of 41. That’s like paying luxury prices for generic painkillers.
- P/E based FV: 30x FY26E EPS → ₹230–₹270
- EV/EBITDA method: 15x → ₹240–₹280
Fair Value Range: ₹230–₹280
If you’re paying above that, you also buy popcorn at multiplexes without blinking.
6. What’s Cooking – News, Triggers, Drama
- Q1 results hotter than your neighbor’s WiFi.
- CFO resigned post results—plot twist.
- 46th AGM on Sept 24, 2025 (expect some drama).
- Dividend record date Sept 12, 2025.
- FII shareholding creeping up (2.17%)—foreigners love the pill story too.
In short: more twists than a daily soap, minus the crying.
7. Balance Sheet
| Assets | ₹278 Cr |
|---|---|
| Liabilities | ₹51 Cr |
| Net Worth | ₹240 Cr |
| Borrowings | ₹9 Cr |
Debt: not Titanic-level, but the ship’s steady. Net worth up, reserves swelling like an ego after gym selfies.
8. Cash Flow – Sab Number Game Hai
| FY23 | FY24 | FY25 |
|---|---|---|
| Ops | ₹47 Cr | ₹35 Cr |
| Investing | -₹58 Cr | -₹25 Cr |
| Financing | -₹0 Cr | -₹9 Cr |
Cash Flow is that freelancer friend—always busy, rarely flush. But at least operations are pumping cash.
9. Ratios – Sexy or Stressy?
| Metric | FY25 |
|---|---|
| ROE | 18.6% |
| ROCE | 23.0% |
| PAT Margin | 19% |
| D/E | 0.03 |
| P/E | 41.1 |
ROCE is hotter than Twitter after an earnings miss. P/E? Expensive, but that’s pharma—high hopes, higher valuations.
10. P&L Breakdown – Show Me the Money
| Year | Revenue | EBITDA | PAT |
|---|---|---|---|
| FY23 | ₹237 Cr | ₹34 Cr | ₹27 Cr |
| FY24 | ₹209 Cr | ₹23 Cr | ₹22 Cr |
| FY25 | ₹269 Cr | ₹51 Cr | ₹55 Cr |
PAT grew 150% in two years—yes, only if you squint at FY24.
11. Peer Comparison
| Peer | Rev (₹Cr) | PAT (₹Cr) | P/E |
|---|---|---|---|
| Sun Pharma | 52,578 | 2,389 | 35.6 |
| Cipla | 27,811 | 1,292 | 23.0 |
| Torrent | 11,516 | 515 | 63.7 |
| Jagsonpal | 283 | 61 | 41.1 |
Jagsonpal: the least drunk guest at a wedding full of finance bros. Small, but dancing well.
12. Miscellaneous – Shareholding, Promoters
- Promoters hold 67.65% (steady).
- FII stake creeping up, DIIs barely there.
- Public holding around 30%.
Promoters seem confident, FIIs slowly stalking, DIIs still ghosting.
13. EduInvesting Verdict™
Jagsonpal is a niche pharma player that quietly doubled profits while larger rivals fought patent wars. Great margins, solid cash, rising FIIs—but valuation is rich.
Final word: “A decent pit stop. But don’t expect business class legroom.”
Written by EduInvesting Team | 26 July 2025
Tags: Jagsonpal Pharma, Q1 FY26, Pharma Analysis, EduInvesting Premium
